Management of Osteoporosis

Publication Date: September 24, 2019

Key Points

Key Points

Patients with non-metastatic cancer may be at risk for osteoporotic fractures due to baseline risks or due to the added risks associated with their cancer therapy.

Clinicians are advised to assess fracture risk using established tools.
  • For those with substantial risk of osteoporotic fracture the clinician should obtain a bone mineral density.

The bone health of all patients may benefit from optimizing nutrition, exercise and lifestyle.

When a pharmacologic agent is indicated, bisphosphonates or denosumab, at osteoporosis-indicated dosages, are the preferred interventions.

Assessment

...Assessment...

...Risk...

...n 1.1. It is recommended that patients...

...dation 1.2. Clinicians should be aware that th...

...ommendation 1.3. Clinicians may use a risk assess...


...ation 2.1. Patients with non-metastatic cancer...

....2. Patients with non-metastatic cancer who are...


Treatment

...Non-pharmacological...

Recommendation 3.1. Clinicians should encoura...

...mmendation 3.2. Clinicians should actively enc...

...commendation 3.3. Clinicians should...


...Pharma...

Recommendation 3.4. For patients with...

...mmendation 3.5. Provided T-score and/or ri...


...gure 1. Algorithm for Maintaining Bone He...


...teoporotic Fracture Risk Factors...


...Loss Associated with Various Cancer Therapies...


...y used Bone Modifying Agents for the Prevent...


...mated Drug Costs for Bone Modifying Agentsa...